top of page
Search
New Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis
The Sponsor is developing AP01 (also referred to in this document as the “study drug”) for use in the treatment of Progressive Pulmonary Fibrosis. AP01 is an experimental drug that may slow your PPF symptoms. You will inhale the study drug using the eFlow Nebuliser System.
Glenn Hearson
Jul 19
Study Investigating the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
Study Investigating the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER)
-
Jul 24, 2024
Efficacy and Safety of Orvepitant in Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis
We have recently commenced a new study led at Nottingham University Hospitals NHS Trust by Gr Gauri Saini, to assess the efficacy and...
-
Nov 17, 2023
Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole
We have just commenced recruiting patients into a new trial which funded by an NIHR HTA Grant with Chief Investigator Professor Andrew...
-
May 25, 2023
Study to assess remote monitoring of patients with an interstitial lung disease
We will be shortly commencing a new study to find out if it is practical for patients with a fibrotic lung disease, to take their own...
-
Aug 26, 2021
Understanding Patient Priorities for Scientific Research on Pulmonary Fibrosis
Dr Amanda Goodwin , Dr Amanda Tatler and Dr Rachel Clifford , along with many other researchers in Translational Medical Science at the...
-
Apr 12, 2021
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study
-
Oct 5, 2020
Nottingham Covid Research Group website launched
The Group will nvestigate the pathogenesis, treatment and complications of lung disease caused by the SARS-CoV-2 virus
-
Mar 30, 2020
bottom of page